Effects of dydrogesterone on the vascular system

References

• Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. J Am Med Assoc 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062–1071
   PubMed Web of Science ®Google Scholar
• Mueck A O, Seeger H. Biochemical markers surrogating on vascular effects of sex steroid hormones. Gynecol Endocrinol 2006; 22: 163–173
   PubMed Web of Science ®Google Scholar
• Schindler A E, Campagnoli C, Druckmann R, Huber J, Pasqualini J R, Schweppe K W, Thijssen J HH. Classification and pharmacology of progestins. Maturitas 2003; 46(Suppl 1)S7–S16
   PubMed Web of Science ®Google Scholar
• Ferenczy A, Gelfand M M, van de Weijer P HM, Rioux J E. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17β-estradiol combined with sequential 5–20 mg dydrogesterone. Climacteric 2002; 5: 26–35
   PubMed Web of Science ®Google Scholar
• Van de Weijer P HM, Scholten P C, van der Mooren M J, Barentsen R, Kenemans P. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone. Climacteric 1999; 2: 101–109
   PubMedGoogle Scholar
• Mendelsohn M E, Karas R H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–1811
   PubMed Web of Science ®Google Scholar
• Cid M C, Schnaper H W, Kleinman H K. Estrogens and the vascular endothelium. Ann N Y Acad Sci 2002; 966: 143–157
   PubMedGoogle Scholar
• Gambacciani M, Monteleone P, Vitale C, Silvestri A, Fini M, Genazzani A R, Rosano G M. Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial. Maturitas 2002; 43: 117–123
   PubMed Web of Science ®Google Scholar
• Levin E L. Endothelins. New Engl J Med 1995; 333: 356–363
   PubMed Web of Science ®Google Scholar
• Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994; 343: 1199–1206
   PubMed Web of Science ®Google Scholar
• Simoncini T, Caruso A, Giretti M S, Scorticati C, Fu X D, Garibaldi S, Baldacci C, Mannella P, Fornari L, Genazzani A R. Effects of dydrogesterone and of its stable metabolite, 20-α-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006; 86(Suppl 4)1235–1242
   PubMedGoogle Scholar
• Rifai N, Ridker P M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47: 403–411
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S, Venugopal S K. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension 2004; 44: 6–11
   PubMed Web of Science ®Google Scholar
• Kwok S, Charlton-Menys V, Pemberton P, McElduff P, Durrington P N. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. Maturitas 2006; 53: 439–446
   PubMed Web of Science ®Google Scholar
• Chia M C. The role of adhesion molecules in atherosclerosis. Crit Rev Clin Lab Sci 1998; 35: 573–602
   PubMed Web of Science ®Google Scholar
• Ridker P M, Hennekens C H, Roitman-Johnson B, Stampfer M J, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92
   PubMed Web of Science ®Google Scholar
• van Baal W M, Kenemans P, Emeis J J, Schalkwijk C G, Mijatovic V, van der Mooren M J, Vischer U M, Stehouwer C D. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71: 663–670
   PubMed Web of Science ®Google Scholar
• Graham I, Daly L, Refsum H, Robinson K, Brattstrom L. Plasma homocysteine as a risk factor for vascular disease. J Am Med Asooc 1997; 277: 1775–1781
   PubMed Web of Science ®Google Scholar
• Hankey G J, Eikelboom J W, Ho W K, Bockxmeer F M. Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust 2004; 181: 314–318
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Netelenbos C, Jakobs C, Popp-Snijders C, Peters-Muller E R, van der Mooren M J. Postmenopausal oral 17β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998; 69: 876–882
   PubMed Web of Science ®Google Scholar
• Chiantera V, Sarti C D, Fornaro F, Farzati A, De Franciscis P, Sepe E, Borrelli A L, Colacurci N. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003; 10: 286–291
   PubMed Web of Science ®Google Scholar
• Smolders R G, de Meer K, Kenemans P, Teerlink T, Jakobs C, van der Mooren M J. Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2004; 117: 55–59
   PubMed Web of Science ®Google Scholar
• Crook D, Godsland I F, Hull J, Stevenson J C. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997; 104: 298–304
   PubMedGoogle Scholar
• Gaspard U J, Wery O J, Scheen A J, Jaminet C, Lefebvre P J. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric 1999; 2: 93–100
   PubMedGoogle Scholar
• Godsland I F, Manassiev N A, Felton C V, Proudler A J, Crook D, Whitehead M I, Stevenson J C. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol (Oxf) 2004; 60: 541–549
   PubMed Web of Science ®Google Scholar
• Dansuk R, Unal O, Karsidag Y K, Turan C. Evaluation of the effects of various gestagens on insulin sensitivity, using homeostatic model assessment, in postmenopausal women on hormone replacement therapy. Gynecol Endocrinol 2004; 20: 1–5
   Google Scholar
• de Kraker A T, Kenemans P, Smolders R G, Kroeks M V, van der Mooren M J. The effects of 17β-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 2004; 49: 253–263
   PubMed Web of Science ®Google Scholar
• Stevenson J C, Rioux J E, Komer L, Gelfand M. 1 and 2 mg 17β-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric 2005; 8: 352–359
   PubMed Web of Science ®Google Scholar
• Cieraad D, Conradt C, Jesinger D, Bakowski M. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. Arch Gynecol Obstet 2006; 274: 74–80
   PubMedGoogle Scholar
• Mijatovic V, Kenemans P, van der Mooren M J, Emeis J J, van Baal W M, Peters-Muller E R, Stehouwer C DA. Postmenopausal oestradiol–dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women. Fibrinolysis Proteolysis 1999; 13: 177–183
   Google Scholar
• Lobo R A, Notelovitz M, Bernstein L, Khan F Y, Ross R K, Paul W L. Lp(a) lipoprotein: relationship to cardiovascular risk factors, exercise, and estrogen. Am J Obstet Gynecol 1992; 166: 1182–1190
   PubMed Web of Science ®Google Scholar
• Shlipak M G, Simon J A, Vittinghoff E, Lin F, Barrett-Connor E, Knopp R H, Levy R I, Hulley S B. Estrogen and progestin, lipoprotein(a) and the risk of recurrent heart disease events after menopause. J Am Med Assoc 2000; 283: 1845–1852
   PubMed Web of Science ®Google Scholar
• Van der Mooren M J, Demacker P NM, Thomas C MG, Rolland R. Beneficial effects on serum lipoproteins by 17β-oestradiol–dydrogesterone therapy in postmenopausal women; a prospective study. Eur J Obstet Gynecol Reprod Biol 1992; 47: 153–160
   PubMed Web of Science ®Google Scholar
• Hänggi W, Lippuner K, Riesen W, Jaeger P, Birkhäuser M. Long term influence of different postmenopausal hormone replacement regimes on serum lipids and lipoprotein(a): a randomized study. Br J Obstet Gynaecol 1997; 104: 708–717
   PubMedGoogle Scholar
• Lokkegaard E, Jovanovic Z, Heitmann B L, Keiding N, Ottesen B, Hundrup Y A, Obel E B, Pedersen A T. Increased risk of stroke in hypertensive women using hormone replacement therapy. Arch Neurol 2003; 60: 1379–1384
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality. A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913
   PubMed Web of Science ®Google Scholar
• Vasan R S, Larson M G, Leip E P, Evans J C, O'Donnell C J, Kannel W B, Levy D. Impact of high–normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297
   PubMed Web of Science ®Google Scholar
• Mueck A O, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 2004; 49: 189–203
   PubMed Web of Science ®Google Scholar
• van Ittersum F J, van Baal W M, Kenemans P, Mijatovic V, Donker A J, van der Mooren M J, Stehouwer C D. Ambulatory – not office – blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens 1998; 11: 1147–1152
   PubMed Web of Science ®Google Scholar
• Kaya C, Cengiz S D, Cengiz B, Akgun G. Long-term effects of low-dose 17β-estradiol plus dydrogesterone on 24-h ambulatory blood pressure in healthy postmenopausal women: a 1-year randomized, prospective study. Gynecol Endocrinol 2007; 23(S1)124–129
   Google Scholar
• Bourne T, Hillard T C, Whitehead M I, Crook D, Campbell S. Oestrogens, arterial status, and postmenopausal women. Lancet 1990; 335: 1470–1471
   PubMed Web of Science ®Google Scholar
• van Baal W M, Kenemans P, Stehouwer C D, Peters-Muller E R, van Vugt J M, van der Mooren M J. Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women. Am J Obstet Gynecol 1999; 181: 1365–1373
   PubMed Web of Science ®Google Scholar
• Luckas M J, Gleeve T, Biljan M M, Buckett W M, Aird I A, Drakeley A, Kingsland C R. The effect of progestagen on the carotid artery pulsatility index in postmenopausal women on oestrogen replacement therapy. Eur J Obstet Gynecol Reprod Biol 1998; 76: 221–224
   PubMed Web of Science ®Google Scholar
• Kessel H, Kamp O, Kenemans P, Mijatovic V, van Baal W M, Visser C A, van der Mooren M J. Effects of 15 months of 17β-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women. Am J Obstet Gynecol 2001; 184: 910–916
   PubMedGoogle Scholar